July 25th, 2008
UPDATE: “I wanted to share an update since my last testimony…..I started the Insulite PCOS system in March of 2007 and in September of 2007 I discovered that I had conceived naturally while on the supplements. My little miracle baby is a healthy 8 week old boy today. Once again I’m forever greatful for the PCOS system!
I have been on the Insulite PCOS system for a little over 3 months now and it is truly a miracle. I feel energized, healthy, and most importantly: normal. A couple of months ago I decided to go off the birth control pill just to see if I could get a period on my own. I’m on my 2nd consecutive menstrual cycle which hasn’t happened since I was a teenager or without the help of birth control pills. I’m currently 30 years old and am having periods on my own, Amazing! I never thought this would happen. Especially since both my daughters were conceived with the help of Glucophage and Clomid.
Thank you to all of those who have taken the time and energy to put together a system that can help people feel normal and enjoy life the way you should. Not to mention all the ingredients in the Insulite PCOS System are healthy and can be taken without having any negative side effects. I’m forever in debt!”
Heather Siegle
Waukee, IA
July 11th, 2008
The Journal of Clinical Endocrinology & Metabolism Vol. 93, No. 7 2670-2678
Karen Elkind-Hirsch, Ory Marrioneaux, Madhu Bhushan, Denise Vernor and Rajat Bhushan
Woman’s Health Research Institute (K.E.-H.), Woman’s Hospital, and Metabolic Center of Louisiana Research Foundation (O.M., M.B., D.V., R.B.), Baton Rouge, Louisiana 70815
Context: Insulin resistance and obesity are common features of the polycystic ovary syndrome (PCOS). Weight loss and use of insulin-lowering drugs have been shown to improve both reproductive and metabolic aspects of PCOS.
Objective: We evaluated exenatide (EX) and metformin (MET), alone and in combination (COM), on menstrual cyclicity, hormonal parameters, metabolic profiles, and inflammatory markers in overweight, insulin-resistant women with PCOS.
Design, Setting, and Participants: Sixty overweight oligoovulatory women with PCOS (body mass index > 27; 18–40 yr) were randomized to one of three treatment groups: MET [1000 mg twice daily (BID)], EX (10 µg BID), or COM (MET 1000 mg BID, EX 10 µg BID) for 24 wk. The primary outcome was menstrual frequency; secondary outcome measures included changes in ovulation rate, insulin action, anthropometric measures, androgen levels, and inflammatory markers.
Results: Forty-two (70%) patients completed the study. COM therapy was superior to EX or MET monotherapy in improving menstrual cyclicity, ovulation rate, free androgen index, and insulin sensitivity measures and reducing weight and abdominal fat. Both EX arms were more effective in promoting weight loss than MET (P = 0.003).
Conclusions: COM appears better than either EX or MET alone on menstrual cycle frequency and hormonal and metabolic derangements. A marked decrease in central adiposity could partly explain the improvements in reproductive function, insulin-glucose parameters, and adiponectin observed in these overweight women with PCOS treated with COM therapy. Larger trials of longer duration are warranted to assess the long-term efficacy and safety of combined EX-MET therapy in overweight women with PCOS.
http://jcem.endojournals.org/cgi/content/abstract/93/7/2670
